Eradication H. pylori is not indicated for the treatment of patients with functional dyspepsia
Therapy to eradicate H. pylori in patients with functional dyspepsia resistant to conventional therapy and diagnosed with H. pylori infection is no more effective than a simple course of antacid drugs.
According to data published in the January issue of the journal Gut, the therapy was aimed at eradicating H. pylori in patients with functional dyspepsia resistant to conventional therapy and diagnosed with H. pylori infection does not lead to a significant improvement in dyspeptic symptoms.
The study included 181 patients with established H. pylori infection and chronic functional dyspepsia, who did not respond to antacid therapy for one week, then to a 2-week course of PPI or placebo.
All patients were randomized into 2 groups: the first received omeprazole (40 mg twice daily) + amoxicillin (1 g twice daily), the second received omeprazole (20 mg once) + placebo. The duration of treatment was 2 weeks, after which all patients were followed for 6 months.
The effectiveness of the treatment was determined by the absence of severe dyspeptic symptoms during the last 3 months of observation.
During the eradication of H. pylori, the frequency of favorable results was not higher than after monotherapy with PPI. Therefore, according to the researchers, the appointment of PPI monotherapy is more appropriate than the PPI + amoxicillin combination therapy.
Four weeks after the end of treatment, the urease breath test was negative in 9 of 92 patients (10%) taking omeprazole and in 46 of 89 patients (52%) receiving omeprazole + amoxicillin.
According to data published in the January issue of Gut, the therapy was aimed at eradicating H. pylori in patients with functional dyspepsia resistant to conventional therapy and diagnosed with H. pylori infection does not significantly improve dyspeptic symptoms.
The study included 181 patients with established H. pylori infection and chronic functional dyspepsia, who did not respond to antacid therapy for one week, then to a 2-week course of PPI or placebo.
All patients were randomized into 2 groups: the first received omeprazole (40 mg twice daily) + amoxicillin (1 g twice daily), the second received omeprazole (20 mg once) + placebo. The duration of treatment was 2 weeks, after which all patients were followed for 6 months.
The effectiveness of the treatment was determined by the absence of severe dyspeptic symptoms during the last 3 months of observation.
During the eradication of H. pylori, the frequency of favorable results was not higher than after monotherapy with PPI. Therefore, according to the researchers, the appointment of PPI monotherapy is more appropriate than PPI + amoxicillin combination therapy.
Four weeks after the end of treatment, the urease breath test was negative in 9 of 92 patients (10%) taking omeprazole and in 46 of 89 patients (52%) receiving omeprazole + amoxicillin.
The degree of "response to therapy" in these groups was determined by the lack of need for additional therapy and the assessment of dyspeptic symptoms for 4 to 6 months after therapy, and amounted to 66% and 62%, respectively.
Thus, the eradication of H. pylori has no significant effect on the development of functional dyspepsia.